Semaglutide has become one of the most talked-about medicines in recent years because of its ability to help people with type 2 diabetes and obesity lose weight.
Doctors have welcomed its benefits for blood sugar control and weight management, but questions remain about how significant weight loss affects other parts of the body, especially bones.
A new study presented at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, suggests that semaglutide may offer an unexpected advantage. Researchers found that people with type 2 diabetes who took semaglutide experienced fewer bone fractures than those using several other weight-loss medications.
Type 2 diabetes affects hundreds of millions of people worldwide. The condition develops when the body becomes resistant to insulin or cannot produce enough insulin to keep blood sugar levels under control.
Over time, high blood sugar can damage blood vessels, nerves, kidneys, eyes, and many other organs. Obesity is one of the major risk factors for type 2 diabetes, which is why weight loss is often a key part of treatment.
Semaglutide belongs to a group of medicines called glucagon-like peptide-1 receptor agonists, commonly known as GLP-1 drugs.
These medicines mimic a natural hormone that helps regulate appetite, slows stomach emptying, and improves blood sugar control. Many patients taking semaglutide lose substantial amounts of weight, often more than with older weight-loss medications.
While weight loss generally improves health, researchers have been concerned about its possible effects on bones. Previous studies have shown that rapid weight loss can sometimes reduce bone density, making bones weaker and increasing the risk of fractures.
Fractures become particularly important as people age because broken bones can reduce mobility, independence, and quality of life.
Scientists at Stanford University wanted to learn whether semaglutide affects bone health differently from other anti-obesity medications. The study was led by Dr. Jairo Noreña and colleagues, who analyzed data from a large electronic health record database known as Atropos Health Eos.
This database includes information from approximately 161 million patients treated in community hospitals and academic medical centers across the United States between 2016 and 2023.
The researchers examined adults with type 2 diabetes who had no previous fractures and were not taking medications for osteoporosis. More than 26,000 people received semaglutide, while over 33,000 people received other treatments, including dulaglutide, phentermine/topiramate, or bupropion/naltrexone.
The results showed that people taking semaglutide experienced greater reductions in body mass index, or BMI, than those taking the comparison medications. BMI is a measurement that estimates body fat based on height and weight. Greater weight loss was expected because semaglutide has consistently shown strong weight-loss effects in previous research.
More importantly, the semaglutide group experienced fewer bone fractures. Researchers recorded 794 fractures among semaglutide users compared with 1,045 fractures in the comparison group. Overall, semaglutide was associated with about a 15 percent reduction in fracture risk.
These findings are encouraging because they suggest that substantial weight loss achieved with semaglutide may not carry the same bone-health concerns that researchers have worried about in the past. However, the study cannot prove that semaglutide directly protected bones because it was observational and relied on existing medical records.
The researchers emphasized that additional prospective studies are needed. Future clinical trials will help determine whether semaglutide truly has a protective effect on bone health and reveal the biological mechanisms involved.
Overall, this study provides promising evidence that semaglutide may help people with type 2 diabetes achieve greater weight loss while potentially reducing fracture risk compared with several other weight-loss treatments.
The study’s large sample size is a major strength, but because it was based on medical records rather than a randomized trial, the findings should be interpreted cautiously. If future research confirms these results, semaglutide could offer important benefits not only for weight management and diabetes control but also for long-term bone health.
If you care about diabetes, please read studies about 5 vitamins that may prevent complication in diabetes, and how to manage high blood pressure and diabetes with healthy foods.
For more health information, please see recent studies about vitamin D and type2 diabetes, and to people with type 2 diabetes, some fruits are better than others.
Source: Stanford University.
